162 results
F-1
EX-10.4
BLRX
Bioline Rx Ltd
24 Sep 10
Registration statement (foreign)
12:00am
of any other person or entity.
COMPENSATION AND BENEFITS
2.1 Base Salary. In consideration of the services to be rendered under this Agreement … , including vesting requirements.
2.4 Benefits. Executive shall be eligible to participate in the benefits made generally available by the Company
6-K
EX-99
BLRX
Bioline Rx Ltd
13 Oct 21
BioLineRx Announces Positive Results from
8:37am
of Care in Stem Cell Mobilization
- Results demonstrate significant cost benefits of using Motixafortide in combination
with G-CSF as standard … ) benefits and net cost savings of ~$17,000 (not including the cost of Motixafortide), versus G-CSF alone. The study findings, combined with model
6-K
EX-99
BLRX
Bioline Rx Ltd
3 Mar 22
BioLineRx Announces Additional Positive Results from
7:10am
to Plerixafor + G-CSF in Stem Cell Mobilization
- Results demonstrate highly significant cost benefits of using Motixafortide in
combination with G-CSF … Health Economics and Outcomes Research (HEOR) team of IQVIA, reinforce and enhance the economic benefits previously seen in the main study evaluating
20FR12B
EX-4.4
BLRX
Bioline Rx Ltd
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
of any other person or entity.
COMPENSATION AND BENEFITS
2.1 Base Salary. In consideration of the services to be rendered under this Agreement … , including vesting requirements.
2.4 Benefits. Executive shall be eligible to participate in the benefits made generally available by the Company
F-1
EX-10.22
BLRX
Bioline Rx Ltd
24 Sep 10
Registration statement (foreign)
12:00am
and there shall be no change in your position with BIJ, in your Salary and all other benefits to which you are entitled, or in any other obligations … and pay you a one time amount equal to the Salary and the benefits referred to in Section 11 that would have been paid to you during the Notice
20FR12B
EX-4.21
4z14yv8
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
F-1
EX-10.3
88fs qi14xyqqh32fzb
24 Sep 10
Registration statement (foreign)
12:00am
20FR12B
EX-4.3
ghbnjc
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
6-K
EX-3
ufrnemuigonpj 0hr
8 Aug 11
Current report (foreign)
12:00am
F-1
EX-10.2
ydqwp99r37cdt2x
24 Sep 10
Registration statement (foreign)
12:00am
20FR12B
EX-4.2
htjagf fsqa
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
6-K
EX-2
ze4qbv2wen86b10 kav
8 Aug 11
Current report (foreign)
12:00am
6-K
EX-99
877he ry0ix45
12 Oct 23
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
7:14am
6-K
EX-99
0gzlhdf
18 Aug 21
BioLineRx Reports Second Quarter 2021 Financial Results
7:01am
F-1
EX-10.5
u25dlwr26
24 Sep 10
Registration statement (foreign)
12:00am
20FR12B
EX-4.5
4gv kmhao
1 Jul 11
Initial registration of securities (foreign private issuers)
12:00am
6-K
EX-99
gwfplle9llcpremvo50
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am